Our data suggest that the weighted combination of ER/PR/HER2 score provides better prognostic discrimination for breast cancer-specific mortality risk among women with ER-positive tumors than that observed for quantitative measures of ER alone. The gene discussed is ERBB2; the disease is breast carcinoma.